A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.

Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.